China bans GSK from drug procurement activities through April 2024

Following an inspection of GSK’s CDMO Poznan, Poland-based site that identified questionable practices, China has decided to ban the company from participating in its centralized drug procurement program through April 29, 2024, according to an English translation of a recent government posting.